期刊文献+

MMP-2,9及TIMP-1与心力衰竭关系的实验研究 被引量:14

Experimental study between MMP2,MMP9,TIMP1 and heart failure
在线阅读 下载PDF
导出
摘要 目的探讨MMP2、MMP9和TIMP1在心力衰竭中的作用和阿托伐他汀治疗心衰的效果。方法用大耳兔做动物模型分3组,假手术(SO)组、心衰对照(HC)组、心衰阿托伐他汀干预(HA)组,HC组与HA组建立心衰模型,造模后6周给予HA组阿托伐他汀干预,用ELISA方法测定术前、术后6周及给药4周后血清中MMP2、MMP9和TIMP1的浓度。结果术前三组兔子MMP2、MMP9和TIMP1的水平,差异无统计学意义(P>0.05)。术后6周,HC组与HA组的MMP2、MMP9和TIMP1的水平均高于SO组,差异有统计学意义(P<0.05)。HA组给药4周后,MMP2、MMP9和TIMP1的水平明显低于HC组(P<0.05)。结论MMP2、MMP9和TIMP1参与了心室重构,阿托伐他汀治疗心衰是有效的。 Objective To investigate the change of MMP2,MMP9,TIMP1’s concentration in serum before and after heart failure and after give medicine.Methods Use the rabbit make animal model and then dispart for 3 groups,they are sham operation(SO) group,heart failure comparison(HC) group,heart failure treat with Atorvastatin(HA)group.HC group and HA group establish heart failure model.After 6 weeks of making model,we give HA group Atorvastatin for treatment,and then use ELISA to determine MMP2,MMP9,TIMP1’s concentration in serum of 3 groups before the opeartion,after 6 weeks of the opeartion and after 4 weeks of give medicine.Results Before opeartion the levels of several targets of 3 groups have no differences and statistics meanings(P>0.05).After 6 weeks of the opeartion,the levels of HC group and HA group all higher than SO group,they have differences and statistics meanings(P<0.05).After 4 weeks of give medicine,the level of 3 tragets of HA group is evidencely lower than HC group(P<0.05).Conclusions MMP2,MMP9 and TIMP1 attend ventricle remodeling,and it is effective that treat heart failure with Atorvastatin.
出处 《医学检验与临床》 2008年第4期29-31,共3页 Medical Laboratory Science and Clinics
关键词 心力衰竭 基质金属蛋白酶 基质金属蛋白酶抑制剂 阿托伐他汀 Heart failure Matrix metalloproteinase Tissue inhibitor of metalloproteinase Atorvastatin
  • 相关文献

参考文献6

二级参考文献85

  • 1林全,王良兴.骨桥蛋白与血管重塑的关系研究进展[J].医学综述,2004,10(12):731-733. 被引量:8
  • 2金霞,张健慧.基质金属蛋白酶基因多态性的研究进展[J].国外医学(遗传学分册),2005,28(2):76-79. 被引量:16
  • 3刘筠,李自普.基质金属蛋白酶及其抑制剂与心肌纤维化的研究进展[J].实用儿科临床杂志,2005,20(8):805-807. 被引量:18
  • 4王凤鸣,王大为,秦玉明.基质金属蛋白酶与心力衰竭[J].实用儿科临床杂志,2005,20(11):1149-1151. 被引量:5
  • 5Coussens LM, Fingleton B, Matrlsian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations [ J]. Science, 2002, 295(5564) :2387-2392.
  • 6Bodh I. Ventricular remodeling after infarction and the extracellular collagen matrix:When is enough enough? [ J 1. Circulation,2003,108 ( 11 ) :1395-1403.
  • 7Jugdutt BI. Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways [J]. Curt Drug Targets Cardiovasc Haematol Disord,2003,3:1-30.
  • 8Wilson EM. Moainie SL, Baskin JM. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling[J].Circulation ,2003,107 (22) :2857-2863.
  • 9Lindsey ML, Mann DL, Entman ML, et al. Extracellular matrix remodeling following myocardial injury[J]. Ann Med,2003,35(5) :316-326.
  • 10Creemers EE. Cieutjens JP, Smits JF. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?[J]. Circ Res,2001,89(3) :201-210.

共引文献38

同被引文献145

引证文献14

二级引证文献92

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部